EUDA Health Holdings Ltd

EUDA Health Holdings Limited (EUDA) is a British Virgin Islands-incorporated company operating primarily in Singapore, with plans for expansion across Southeast Asia. The company's mission is to provide affordable and accessible high-quality, personalized healthcare through its proprietary platform. EUDA integrates Artificial Intelligence (AI) and Machine Learning (ML) to offer real-time actionable analytics for quick analysis, accurate diagnosis, and business decisions, aiming to bridge gaps in the fragmented healthcare industry. The company generates revenue from medical services, product sales, and property management services. In January 2020, EUDA acquired Super Gateway Group Limited (SGGL), a property management service company, with the aim of building an omni-channel healthcare and products platform with cross-sell opportunities ¹. On November 17, 2022, EUDA consummated a business combination with 8i Acquisition 2 Corp., resulting in EUDA becoming a wholly-owned subsidiary of the combined entity, which subsequently changed its name to EUDA Health Holdings Limited ².

The digital health industry, where EUDA operates, is described as relatively young, in its early growth stages, and evolving. The global telehealth and telemedicine market is projected to reach USD 191.7 billion by 2025, up from an estimated USD 38.7 billion in 2020, driven by factors such as a rising and aging population, the need to expand healthcare access, growing prevalence of chronic diseases, physician shortages, advancements in telecommunications, and government support ³. Healthcare costs globally have outpaced economic growth, with spending growing by 3.9% annually between 2000 and 2017, compared to global GDP growth of 3.0% ⁴. In Southeast Asia, healthcare expenditure is projected to grow by 11.5% annually to US$115.9 billion by 2025 ⁵.

EUDA's core business model revolves around its proprietary platform, which integrates AI and ML to offer a holistic, connected healthcare ecosystem. Revenue is generated from medical services fees, primarily from specialty medical visits where EUDA acts as a principal connecting physicians to patients, and property management service fees, which are contractually recurring from common area management and security management services for retail and residential properties ⁶. The company also has a Digital Health Marketplace (DHM) for consumer health and wellness products, including dietary supplements, skincare, and healthy snacks ⁷.

The company's services are divided into four verticals: Healthcare, Lifestyle & Wellness, Health Plans, and Enablement. Healthcare solutions include 24/7 medical urgent care, digital pharmacy solutions, and diagnostic and monitoring services. The wellness vertical encompasses an e-commerce marketplace for health and supplement products, home care services, a fitness segment, and men's and women's health content. Health plans will offer monthly subscription packages for corporations and individuals covering telehealth services, online pharmacy, and health screenings ⁸. The property management services, categorized under Home Care Service line from 2023, are intended to evolve into home-based medical services ⁹.

For the year ended December 31, 2022, total revenues decreased by approximately $0.7 million, or 6.7%, to approximately $9.8 million, compared to approximately $10.5 million for the year ended December 31, 2021 ¹⁰. Cost of revenues increased by approximately $0.2 million, or 3.0%, to approximately $6.5 million in 2022 from approximately $6.3 million in 2021 ¹¹. Gross profit decreased by approximately $0.9 million, or 21.0%, to approximately $3.4 million in 2022 from approximately $4.2 million in 2021 ¹². The overall gross profit percentage was 34.1% in 2022, down from 40.3% in 2021 ¹³. Operating expenses increased by approximately $9.9 million, or 181.6%, to approximately $15.4 million in 2022 from approximately $5.5 million in 2021 ¹⁴. The company incurred a net loss of approximately $24.9 million in 2022, a significant shift from a net income of approximately $0.9 million in 2021 ¹⁵. Diluted EPS was $(2.07) in 2022, compared to $0.09 in 2021 ¹⁶. As of December 31, 2022, the company had a negative working capital deficit of approximately $4.1 million and cash and restricted cash of approximately $0.8 million ¹⁷. Total liabilities were $29,136,071 ¹⁸.

Revenue from medical services increased by approximately $0.3 million, or 5.9%, to approximately $6.1 million in 2022 from approximately $5.7 million in 2021, driven by an increased number of employees/patients from corporate clients utilizing specialty healthcare services ¹⁹. The number of corporate clients utilizing specialty healthcare services increased from approximately 800 in 2021 to approximately 860 in 2022 ²⁰. Product sales revenue decreased by approximately $0.2 million, or 95.7%, to approximately $11,000 in 2022 from approximately $0.3 million in 2021, due to decreased demand for facial recognition and temperature measurement monitor systems as the COVID-19 pandemic eased ²¹. Property management services revenue decreased by approximately $0.8 million, or 17.4%, to approximately $3.8 million in 2022 from approximately $4.6 million in 2021, primarily due to a decrease in the number of managed properties ²². The gross profit percentage for medical services decreased by 8.9% to 41.8% in 2022, mainly because the company directly utilized third-party clinic service providers starting April 2022, with less service discounts ²³. The gross profit percentage for product sales decreased by 472.9% to (437.7)% in 2022, primarily due to lower customer demand and a write-off of non-saleable items ²⁴. Property management services gross profit percentage decreased by 4.3% to 23.1% in 2022, attributed to increased salary and benefits for property management employees not passed on to customers ²⁵.

Significant operational developments during the period include the consummation of the business combination on November 17, 2022 ²⁶. The company also incurred a loss from change in prepaid forward purchase liabilities of approximately $12.9 million in 2022 due to fair value accounting, as the stock price significantly dropped after the business combination ²⁷. An impairment loss on long-lived assets and goodwill of approximately $1.1 million was recognized in 2022 ²⁸. The company also disposed of 100% of the equity interest in its subsidiary, The Good Clinic Private Limited (TGC), to an unrelated third party for SG$1.0 on March 1, 2022, recognizing a gain of $30,055 ²⁹.

Management explicitly states that the company has an ongoing need to raise additional cash from outside sources to fund its expansion plan and related operations ³⁰. The successful transition to profitable operations is dependent upon achieving a level of revenues adequate to support the company's cost structure ³¹. The company is in active discussions with underwriters regarding a potential financing transaction through the issuance of convertible notes, with a goal for such transactions to be completed in the fourth quarter of 2023 to improve liquidity and capital resource needs ³².

A major growth area for EUDA is driving greater adoption with existing clients by expanding the populations to which it offers services. This includes expanding digital health options to more members within health plans and system-wide expansion within health systems that may start with a single hospital or region. The company also plans to increase adoption within Singapore by continually increasing awareness and loyalty to its solution through new and complementary products and services, third-party connections, and strategic alliances ³³. Furthermore, EUDA aims to refine and enhance user experience through targeted patient and medical provider engagement campaigns, best practices training, and operational support. It is building robust data repositories to strengthen predictive models and multi-channel marketing strategies to enhance targeted campaigns, and plans to invest heavily in marketing technologies to increase client touchpoints ³⁴.

Another significant growth vector is increasing penetration by adding new clients within its core verticals. EUDA plans to continue investing in its direct sales force and channel management capabilities to sustain growth and client support, particularly targeting large employers and small-medium enterprises. The company believes its B2B2C model will yield higher growth with lower customer acquisition costs compared to a direct B2C model ³⁵. Resources will also be directed into new marketing technologies and campaigns to support sales force lead generation and new client acquisition ³⁶.

The company intends to invest in new clinical specialties, leveraging its scalable platform. Current offerings range from chronic disease management, medical tourism, mental health, to men's and women's health. Future plans include offering direct access to behavioral health professionals for conditions like anxiety and smoking cessation, and expanding into standalone dermatology services, second opinions, and chronic conditions such as diabetes ³⁷. EUDA also plans to expand its solutions across additional care settings and explore ancillary opportunities like home care, post-discharge services, wellness, screening, and chronic care, taking a holistic approach to improve client outcomes through Health, Fitness, and Nutritional modules. It is also looking to provide campus clinics, workplace health services, and medical emergency assistance ³⁸.

Operationally, EUDA is constantly investing in AI technology to expand patient engagement, improve efficiencies, reduce care costs, and promote better care coordination. An example is an AI deployment for a patient-provider matching tool that synthesizes patient preferences for optimal matches ³⁹. Continued investment in interoperability, including remote patient monitoring, advanced analytics, lab services, and home delivery of pharmaceuticals, is expected to expand use cases. Strategic partnerships with innovative companies are also being pursued to develop unique products and services accessible directly through EUDA interfaces ⁴⁰.

Planned capital allocation includes continued investment in research and development to enhance existing services and introduce new high-quality services ⁴¹. The company's capital expenditure for equipment was approximately $18,000 in 2022 ⁴². In terms of financing, EUDA raised an aggregate of $940,000 from the sale of 940,000 restricted ordinary shares at $1.00 per share in a private placement between May 16 and May 22, 2023 ⁴³. Additionally, between May and June 2023, EUDA settled debt obligations totaling $1,617,606 by issuing 1,345,739 ordinary shares to three creditors, two of whom are related parties ⁴⁴.

Management explicitly flagged that the company has experienced recurring losses from operations and negative cash flows from operating activities since 2020 ⁴⁵. The digital health industry's immaturity and rapid evolution, coupled with uncertainties regarding demand and consumer acceptance, pose a risk to the company's success ⁴⁶. A potential economic recession and financial market uncertainty, along with inflation and rising interest rates, may affect customer financial performance and demand ⁴⁷. The company's ability to retain active customers and attract new ones is crucial, as failure to do so could result in future revenue loss and deteriorate liquidity and operating cash flow ⁴⁸.

EUDA faces substantial risks, including its current non-compliance with Nasdaq's continued listing standards, which could lead to delisting ⁴⁹. The company's independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about its ability to continue as a "going concern" due to a negative working capital deficit of approximately $4.1 million, cash and restricted cash of approximately $0.8 million as of December 31, 2022, recurring losses, and negative cash flows from operations since 2020 ⁵⁰. Material weaknesses in internal control over financial reporting were identified for the years ended December 31, 2022 and 2021, related to insufficient financial reporting and accounting personnel with U.S. GAAP knowledge and a lack of proper mechanisms to assess third-party specialists ⁵¹. The company will require additional funding through debt or equity securities to support operations and growth, which may not be available on acceptable terms or at all, potentially leading to significant dilution for existing shareholders ⁵². A significant portion of revenue is derived from corporate clients, and the loss of these clients would materially adversely affect the business ⁵³. The digital health industry is highly competitive and subject to rapid technological change, posing risks if EUDA cannot effectively compete or innovate ⁵⁴. Foreign exchange risks exist due to operations in multiple countries (Singapore, Vietnam, Malaysia) and fluctuating exchange rates ⁵⁵. Dependence on strategic relationships with third parties and partners for growth, and the ability to maintain and expand a network of qualified providers, are critical ⁵⁶. Reliance on third-party technology services and internal systems for service delivery means any failure or interruption could lead to litigation, reputational harm, and loss of clients ⁵⁷. The company currently holds no issued patents, relying on copyright, trademark, and trade secret laws, which may not provide adequate protection against unauthorized use or development of similar technology by competitors ⁵⁸. Inaccurate or incomplete data provided to clients through the platform could damage reputation and harm the ability to attract and retain clients ⁵⁹. Security measure failures or breaches, including cyber-attacks, could result in unauthorized access to sensitive client or patient data, leading to significant liabilities, reputational harm, and loss of sales and clients ⁶⁰.

Management's message to shareholders conveys a tone of strategic ambition and a commitment to leveraging technology to address industry challenges, despite acknowledging the company's early stage and financial hurdles. They emphasize EUDA's mission to make high-quality, personalized healthcare affordable and accessible for all patients through its proprietary AI and ML-integrated platform ⁶¹. A key strategic priority is the continuous building of a consumer-centric digital ecosystem to provide access to quality healthcare while keeping costs affordable ⁶². Management also highlights the importance of incorporating technology into the traditional medical services market to create an end-to-end ecosystem offering a comprehensive suite of healthcare and wellness services ⁶³. They are actively pursuing growth by driving greater adoption with existing clients, increasing penetration with new clients in core verticals, investing in new clinical specialties, expanding across care settings and use cases, and investing in digitalization and innovation for digital care capabilities ⁶⁴. Management explicitly states the company's ongoing need to raise additional cash from outside sources to fund its expansion plan and related operations, with a goal to complete convertible notes financing in the fourth quarter of 2023 to improve liquidity ⁶⁵. They also acknowledge the recurring losses from operations and negative cash flows since 2020, and that successful transition to profitable operations depends on achieving adequate revenues to support the cost structure ⁶⁶.